Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment

Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander

(2018) Corinne Maurice-Dror et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.

(2018) Kathryn Cecilia Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity

(2017) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity

(2017) Stanleyson V. Hato et al.   Oncotarget

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

(2017) Zibing Wang et al.   OncoImmunology

Chemotherapy and immunotherapy: mapping the road ahead

(2016) Alistair M Cook et al.   CURRENT OPINION IN IMMUNOLOGY

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy

(2015) Kailin Xing et al.   BMC IMMUNOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations

(2015) W. Joost Lesterhuis et al.   Scientific Reports

Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions

(2015) Raymond Elsoueidi et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics

(2014) S. V. Hato et al.   CLINICAL CANCER RESEARCH

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy

(2014) Alison M. McDonnell et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Automated identification of stratifying signatures in cellular subpopulations

(2014) Robert V. Bruggner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity

(2013) W. Joost Lesterhuis et al.   PLoS One

The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival

(2011) Arash S. Saffar et al.   CURRENT DRUG TARGETS

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

(2010) Rupal Ramakrishnan et al.   JOURNAL OF CLINICAL INVESTIGATION

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

(2010) Kaan Harmankaya et al.   MEDICAL ONCOLOGY

Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function

(2008) Istvan Szatmari et al.   EMBO JOURNAL